Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01688960 · ClinicalTrials.gov registry record · Phase 1
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01688960 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT01688960, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, ascending, multiple dose study of nesvacumab (REGN910/ SAR307746) in combination with aflibercept ("ziv-aflibercept" in the U.S.)
Interventions
- DRUG nesvacumab (REGN910/ SAR307746)
- DRUG aflibercept (ziv-aflibercept)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01688960
The ClinicalTrials.gov registry entry for NCT01688960 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which nesvacumab (REGN910/ SAR307746) is the first listed.
NCT01688960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01688960 about?
NCT01688960 is a clinical study titled "Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies". This is an open-label, multicenter, ascending, multiple dose study of nesvacumab (REGN910/ SAR307746) in combination with aflibercept ("ziv-aflibercept" in the U.S.)
What is the current status of trial NCT01688960?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2012-10. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01688960?
The interventions under investigation include: nesvacumab (REGN910/ SAR307746) (DRUG), aflibercept (ziv-aflibercept) (DRUG).
Who is sponsoring clinical trial NCT01688960?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.